A 28-year-old man from Delhi presents with a 10-day history of fever, headache, and abdominal pain. He returned from a village in Uttar Pradesh 3 weeks ago where he consumed contaminated water. On examination, he has a temperature of 39.5°C, relative bradycardia, hepatosplenomegaly, and a faint rose-coloured rash on the trunk. His blood culture is positive for a gram-negative bacillus. Widal test shows O antigen titre of 1:160 and H antigen titre of 1:320. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis & Rationale This patient has **uncomplicated enteric fever** (typhoid) confirmed by positive blood culture in the first 2 weeks of illness, supported by classic clinical features and a rising Widal titre pattern. ### Key Clinical Features **Key Point:** The classic triad of enteric fever is fever, headache, and abdominal pain; rose spots (faint macules on trunk) and relative bradycardia are pathognomonic signs. **High-Yield:** Blood culture is the gold standard for diagnosis in the first 2 weeks; Widal test has poor specificity (endemic areas, prior vaccination, cross-reactivity) and should NOT guide initial therapy. ### Antibiotic Management Algorithm ```mermaid flowchart TD A[Enteric Fever Confirmed<br/>Blood Culture Positive]:::outcome --> B{Susceptibility Pattern?}:::decision B -->|Uncomplicated,<br/>No Resistance| C[Ceftriaxone 2g IV<br/>12-hourly × 7-10 days]:::action B -->|Fluoroquinolone-Resistant<br/>Salmonella typhi| D[Ceftriaxone or<br/>Azithromycin]:::action B -->|XDR Typhoid<br/>Cephalosporin-Resistant| E[Carbapenems or<br/>Azithromycin]:::action C --> F[Defervescence in 3-5 days<br/>Clinical improvement]:::outcome D --> F E --> F ``` ### Current Antibiotic Recommendations (India, 2023) | Phenotype | First-Line Agent | Dose | Duration | |-----------|------------------|------|----------| | **Susceptible** | Ceftriaxone | 2 g IV 12-hourly | 7–10 days | | **FQRST** (Fluoroquinolone-Resistant) | Ceftriaxone or Azithromycin | 2 g IV 12-hourly or 500 mg daily | 7–10 days | | **XDR** (Extensively Drug-Resistant) | Carbapenems (meropenem) or Azithromycin | 1 g IV 8-hourly or 500 mg daily | 7–14 days | **Clinical Pearl:** In India, fluoroquinolone-resistant Salmonella typhi (FQRST) is now endemic in many regions; empiric fluoroquinolone monotherapy is **no longer recommended** as first-line, even though Widal shows high titres. **Key Point:** Ceftriaxone remains the safest, most effective empiric choice for uncomplicated enteric fever in India pending culture sensitivity results. ### Why Ceftriaxone Now? 1. **Broad coverage** of susceptible and FQRST strains 2. **Excellent CNS penetration** (relevant if complications develop) 3. **Rapid defervescence** (fever resolves in 3–5 days) 4. **Low resistance rates** compared to fluoroquinolones in endemic regions **Tip:** Do NOT delay antibiotic therapy awaiting sensitivity results; start empirically with ceftriaxone once blood culture is sent. De-escalate only if sensitivity shows susceptibility to cheaper agents (e.g., fluoroquinolone in susceptible strains).